DaVita HealthCare (DVA) came out with quarterly earnings of $2.24 per share, beating the Zacks Consensus Estimate of $2.21 per share. This compares to earnings of $1.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.36%. A quarter ago, it was expected that this kidney dialysis provider would post earnings of $2.76 per share when it actually produced earnings of $2.59, delivering a surprise of -6.16%.Over the last four quart ...

International Operations - As of December 31, 2024, the company operated 509 outpatient dialysis centers in 13 countries, serving approximately 80,300 patients[76] - The international dialysis operations have shown steady growth due to acquisitions and development of outpatient dialysis centers in strategic markets[76] - The international outpatient dialysis centers are distributed across various countries, with Brazil having the highest number at 100 centers[78] - The company continues to expand its international dialysis operations, facing competition for acquisition targets and physician relationships in new markets[136] Regulatory Compliance - The company faces a complex regulatory environment, requiring significant resources to monitor compliance with federal, state, and international laws[80] - Delays in obtaining Medicare certifications have been experienced, although recent changes have helped mitigate some of these delays[86] - The company’s dialysis centers are certified by CMS and must comply with various state licensing requirements to operate[83] - Violations of the federal Anti-Kickback Statute and Stark Law could lead to severe penalties, including exclusion from Medicare and Medicaid programs[90][95] - The federal government has prosecuted various alleged false claims and fraud against Medicare and state healthcare programs, including billing for services not rendered and coding errors[103] - The company may face criminal, civil, or administrative sanctions if found in violation of state fraud and abuse laws, including potential exclusion from Medicaid and other healthcare programs[104] - Violations of the corporate practice of medicine and fee-splitting laws may result in disciplinary action against physicians and forfeiture of revenues from payors[107] - The Civil Monetary Penalties Statute allows for substantial penalties, including assessments of up to three times the total amount claimed for each item or service[108] - The Foreign Corrupt Practices Act prohibits improper payments to foreign officials, with violations potentially resulting in fines and adverse impacts on business practices[109] - The Health Insurance Portability and Accountability Act (HIPAA) requires the implementation of safeguards to protect patient health information, with penalties for non-compliance[110] - The company must comply with evolving privacy and data protection laws, including the GDPR, which can impose fines of up to 4% of worldwide turnover or €20 million[117] - The California Consumer Privacy Act (CCPA) and other state laws provide expanded privacy protections, potentially leading to increased compliance costs and legal risks[119] - The evolving healthcare regulatory landscape, including potential changes to the ACA, poses significant uncertainty for the company's operations[126] Financial Performance and Risks - Corporate administrative support costs include labor, benefits, and professional fees, impacting the consolidated general and administrative expenses[79] - The company has invested substantial resources in CMMI payment models aimed at improving kidney care and reducing expenditures, with the ETC mandatory payment model launched in 30% of dialysis clinics[123] - The company is highly sensitive to the percentage of patients with higher-paying commercial health insurance, with potential adverse impacts from legislative changes affecting premium tax credits[124] - The 21 Century Cures Act has increased the percentage of patients on Medicare Advantage plans compared to Medicare Part B plans, broadening access to enhanced benefits[127] - Recent price transparency regulations require health plans to publish negotiated rates and out-of-pocket costs for services, impacting operational transparency[128] - The implementation of California's AB 290, which limits reimbursement for certain services, could materially impact the company's financial condition[131] - A hypothetical increase in interest rates of 100 basis points could reduce net income by approximately $4.2 million, $4.8 million, and $21.4 million for the years ended December 31, 2024, 2023, and 2022, respectively[432] - The company is primarily self-insured for various liabilities, which may expose it to risks if future claims exceed coverage[139] Workforce and Diversity - As of December 31, 2024, the company employed approximately 76,000 teammates, with about 75% located in the U.S., highlighting its workforce scale[142] - As of December 31, 2024, 84% of U.S. teammates feel a sense of belonging within the DaVita community[147] - DaVita's workforce in the U.S. is composed of 78% women and 58% people of color, with 73% of managers and 62% of directors being women[148] - Approximately 58% of U.S. managers were promoted from within in 2024, reflecting the company's commitment to internal career development[153] - The company has 2,400 teammates currently enrolled in the Bridge to Your Dreams program, which supports high-performing individuals pursuing nursing degrees[152] - DaVita's total rewards program includes financial wellness elements such as a 401(k) match and employee stock purchase plan (ESPP)[156] - DaVita's Board is composed of 40% women and 20% people of color, indicating a commitment to diversity at the leadership level[148] - The company has implemented a structured talent mobility effort to empower teammates to explore alternative career pathways[155] Safety and Compliance Programs - DaVita's safety programs include monthly OSHA and infection control audits to ensure compliance and promote a safe working environment[159] Innovation and Development - The company’s transplant software business, MedSleuth, enhances connectivity among transplant candidates and centers, improving patient outcomes[77] - DaVita Venture Group focuses on innovative products and solutions for kidney disease, identifying opportunities for acquisitions and partnerships in digital health and medical devices[77] Competition - The company faces intense competition in the U.S. dialysis industry from both established providers and new entrants, affecting patient acquisition and retention strategies[135]

Contact: Investor Relations DaVita Inc. ir@davita.com DaVita Inc. 4th Quarter 2024 Results Denver, Colorado, February 13, 2025 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25 annivers ...

DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended December 31, 2024."Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enh ...

DaVita Inc. (DVA) is scheduled to report fourth-quarter 2024 results on Feb. 13, after the closing bell.See the Zacks Earnings Calendar to stay ahead of market-making news.In the last reported quarter, the company’s earnings per share (EPS) of $2.59 lagged the Zacks Consensus Estimate by 6.2%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 10.6%, on average.For fourth-quarter 2024, the Zacks Conse ...

In the latest trading session, DaVita HealthCare (DVA) closed at $177.35, marking a +0.16% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.72% for the day. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.35%.The kidney dialysis provider's stock has climbed by 16.85% in the past month, exceeding the Medical sector's gain of 4.51% and the S&P 500's gain of 1.02%.Investors will be eagerly watching for the performance of DaVita HealthCare in its ...

DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in num ...

DaVita HealthCare (DVA) closed the most recent trading day at $173.77, moving +0.32% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.47%. On the other hand, the Dow registered a loss of 0.31%, and the technology-centric Nasdaq decreased by 0.51%.Coming into today, shares of the kidney dialysis provider had gained 15.82% in the past month. In that same time, the Medical sector gained 3.2%, while the S&P 500 gained 1.67%.Analysts and investors alike wi ...

Investors might want to bet on DaVita HealthCare (DVA) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a ch ...

Big things happened this weekend.In a calculated move, a Chinese AI company released its newest large-language model (LLM), on the same day as the presidential inauguration. Though it took a week for most market participants to take notice, all are now paying attention. DeepSeek, the latest contender in the AI landscape, has made waves by developing an equally powerful algorithm at a fraction of the cost—and it’s open-source. The implications of this are quite significant, as is evident from the price actio ...